1. Yadav, M. K. et al. Transcription factor MafB is a marker of tumor-associated macrophages in both mouse and humans. Biochem. Biophys. Res. Commun. (2019) doi:10.1016/j.bbrc.2019.10.125.
2. Russell, R. et al. Loss of the transcription factor MAFB limits β-cell derivation from human PSCs. Nat. Commun. 11, 1–15 (2020).
3. Moriguchi, T. et al. MafB Is Essential for Renal Development and F4/80 Expression in Macrophages. Mol. Cell. Biol. 26, 5715–5727 (2006).
4. Sadl, V. S. et al. The mouse Kreisler (Krml1/MafB) segmentation gene is required for differentiation of glomerular visceral epithelial cells. Dev. Biol. 249, 16–29 (2002).
5. Lopez-Pajares, V. et al. A LncRNA-MAF:MAFB transcription factor network regulates epidermal differentiation. Dev. Cell 32, 693–706 (2015).
6. Miyai, M. et al. Transcription Factor MafB Coordinates Epidermal Keratinocyte Differentiation. J. Invest. Dermatol. 136, 1848–1857 (2016).
7. Nishimura, W. et al. A switch from MafB to MafA expression accompanies differentiation to pancreatic β-cells. Dev. Biol. 293, 526–539 (2006).
8. Hang, Y. & Stein, R. MafA and MafB activity in pancreatic β cells. Trends in Endocrinology and Metabolism vol. 22 364–373 (2011).
9. Goudot, C. et al. Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus Macrophages. Immunity 47, 582-596.e6 (2017).
10. Matcovitch-Natan, O. et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science (80-. ). 353, (2016).
11. Shichita, T. et al. MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat. Publ. Gr. 23, (2017).
12. Hamada, M. et al. MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. Nat. Commun. 5, 1–14 (2014).
13. Sato, Y. et al. A mutation in transcription factor MAFB causes Focal Segmental Glomerulosclerosis with Duane Retraction Syndrome. Kidney Int. 94, 396–407 (2018).
14. Zankl, A. et al. Multicentric carpotarsal osteolysis is caused by mutations clustering in the amino-terminal transcriptional activation domain of MAFB. Am. J. Hum. Genet. 90, 494–501 (2012).
15. Auffray, C. et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science (80-. ). 317, 666–670 (2007).
16. Dick, S. A. et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat. Immunol. 20, 29–39 (2019).
17. Clemente, C. et al. MT4-MMP deficiency increases patrolling monocyte recruitment to early lesions and accelerates atherosclerosis. Nat. Commun. 9, 1–16 (2018).
18. Cochain, C. et al. Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ. Res. 122, 1661–1674 (2018).
19. Krishnasamy, K. et al. Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. Nat. Commun. 8, 1–14 (2017).
20. Puranik, A. S. et al. Kidney-resident macrophages promote a proangiogenic environment in the normal and chronically ischemic mouse kidney. Sci. Rep. 8, 1–15 (2018).
21. Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
22. Koshida, R., Oishi, H., Hamada, M., Takei, Y. & Takahashi, S. MafB is required for development of the hindbrain choroid plexus. Biochem. Biophys. Res. Commun. 483, 288–293 (2017).
23. Sanjurjo, L., Aran, G., Roher, N., Valledor, A. F. & Sarrias, M.-R. AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. J. Leukoc. Biol. 98, 173–184 (2015).
24. Liao, C. Te et al. Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes. Kidney Int. 91, 1088–1103 (2017).
25. Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science (80-. ). 344, 921–925 (2014).
26. Cuevas, V. D. et al. MAFB Determines Human Macrophage Anti-Inflammatory Polarization: Relevance for the Pathogenic Mechanisms Operating in Multicentric Carpotarsal Osteolysis. J. Immunol. 198, 2070–2081 (2017).
27. Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism vol. 30 36–50 (2019).
28. Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Research vol. 79 4557–4567 (2019).
29. Van Overmeire, E., Laoui, D., Keirsse, J., Van Ginderachter, J. A. & Sarukhan, A. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Frontiers in Immunology vol. 5 (2014).
30. Yang, L. & Zhang, Y. Tumor-associated macrophages: from basic research to clinical application. Journal of hematology & oncology vol. 10 58 (2017).
31. Kim, J. & Bae, J. S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators of Inflammation vol. 2016 (2016).
32. Funes, S. C., Rios, M., Escobar-Vera, J. & Kalergis, A. M. Implications of macrophage polarization in autoimmunity. Immunology vol. 154 186–195 (2018).
33. Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887–904 (2018).
34. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).
35. Pinto, M. L. et al. The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer. Front. Immunol. 10, 1875 (2019).
36. Komohara, Y., Ohnishi, K., Kuratsu, J. & Takeya, M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216, 15–24 (2008).
37. Komohara, Y. et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 102, 1424–1431 (2011).
38. Niino, D. et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol. Int. 60, 278–283 (2010).
39. Komohara, Y. et al. Clinical significance of <scp>CD</scp> 163 + tumor‐associated macrophages in patients with adult T‐cell leukemia/lymphoma. Cancer Sci. 104, 945–951 (2013).
40. Shigeoka, M. et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 104, 1112–1119 (2013).
41. Komohara, Y., Jinushi, M. & Takeya, M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Science vol. 105 1–8 (2014).
42. Rakaee, M. et al. Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia (United States) 21, 282–293 (2019).
43. Ruffell, B. & Coussens, L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell vol. 27 462–472 (2015).
44. Heusinkveld, M. & van der Burg, S. H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 9, 216 (2011).
45. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology vol. 23 549–555 (2002).
46. Qian, B. Z. & Pollard, J. W. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell vol. 141 39–51 (2010).
47. Wu, L. & Zhang, X. H.-F. Tumor-Associated Neutrophils and Macrophages—Heterogenous but Not Chaotic. Front. Immunol. 11, 3117 (2020).
48. Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N. & Muschel, R. J. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene 2016 3544 35, 5735–5745 (2016).
49. Wyckoff, J. et al. A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors. Cancer Res. 64, 7022–7029 (2004).
50. DeNardo, D. G. et al. CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages. Cancer Cell 16, 91–102 (2009).
51. Wei, C. et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol. Cancer 2019 181 18, 1–23 (2019).
52. Zhu, X.-D. et al. High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma. https://doi.org/10.1200/JCO.2007.15.6521 26, 2707–2716 (2016).
53. Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495–499 (2017).
54. Kubota, K. et al. CD163+CD204+ tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma. Sci. Rep. 7, 1755 (2017).
55. Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T. & Kusmartsev, S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl. Acad. Sci. U. S. A. 114, 1117–1122 (2017).
56. Okazaki, T. & Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends in Immunology vol. 27 195–201 (2006).
57. Qu, Q.-X., Huang, Q., Shen, Y., Zhu, Y.-B. & Zhang, X.-G. The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer. Tumor Biol. 37, 5031–5037 (2016).
58. Tran, M. T. N. et al. MafB is a critical regulator of complement component C1q. Nat. Commun. 8, 1700 (2017).
59. Yu, H. et al. Transcription Factor MafB Promotes Hepatocellular Carcinoma Cell Proliferation through Up-Regulation of Cyclin D1. Cell. Physiol. Biochem. 39, 700–708 (2016).
60. Yang, L.-S. et al. SUMOylated MAFB promotes colorectal cancer tumorigenesis. Oncotarget 7, 83488 (2016).
61. Li, L. et al. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation. Theranostics 11, 1672 (2021).